SN BioScience
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Seoul, Seoul, South KoreaPhone Number
+82 317573841Website
www.snbioscience.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About SN BioScience
SN BioScience is a research and development-focused company specializing in drug delivery systems and innovative technologies, particularly in the field of nano-medicine. The company is dedicated to ensuring patient safety while providing access to investigational therapies for various diseases. Their current pipeline includes promising treatments for small cell lung cancer (SCLC) and other conditions. SN BioScience aims to attract talented individuals to join their mission of advancing healthcare through innovative solutions.Explore more
Popular SearchesSN BioScienceSIC Code 87,873NAICS Code 54,541Show moreSN BioScience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SN BioScience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SN BioScience had a recent Job posting/layoffs
Earning: See what the market has to say on SN BioScience recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once SN BioScience has new funding data
Check if SN BioScience has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at SN BioScience
SN BioScience, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when SN BioScience launches new products
Check out if SN BioScience is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined SN BioScience as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
SN BioScience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SN BioScience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SN BioScience.
SN BioScience Tech Stack
A closer look at the technologies used by SN BioScience
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Research & Development, Compliance, Medical Research, Pharmaceuticals, Regulations
Project
Product Management, Compliance, Legal Affairs
Project
SN BioScience News & Media
SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.
SEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer...SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/ -- SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of...Following the FDA, EMA also Grants an Orphan Drug Designation of SN Bioscience's Nano Anti-Cancer Drug 'SNB-101' for Small Cell Lung Cancer.
SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- SN Bioscience Co., Ltd. (CEO Park Young-hwan) announced on May 24 that European Medicines Agency(EMA) had granted an orphan drug designation for small cell lung cancer(SCLC), a rare disease, for SNB-101 (API: SN-38) which is a new polymer...SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer
SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 was designated as an orphan drug for small cell lung cancer and pancreatic cancer in July of last year and February of this year, respectively. By receiving
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SN BioScience
Sign Up For FreeTo access detailed company insights
SN BioScience is a research and development-focused company specializing in drug delivery systems and innovative technologies, particularly in the field of nano-medicine. The company is dedicated to ensuring patient safety while providing access to investigational therapies for various diseases. Their current pipeline includes promising treatments... Read More
